Rights and permissions
About this article
Cite this article
IV-to-oral antibacterial switch programme avoids unnecessary costs. Pharmacoecon. Outcomes News 115, 9 (1997). https://doi.org/10.1007/BF03271676
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03271676